'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Ajanta Pharma has increased 13.78% to Rs 1302.65 crore. Operating profit margin has declined from 28.85% to 26.97%, leading to 6.36% rise in operating profit to Rs 351.35 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 20.54% to 16.11%. Purchase of finished goods cost rose from 3.90% to 4.02%. Employee cost decreased from 24.45% to 23.56%. Other expenses rose from 22.65% to 28.98%.
Other income fell 0.53% to Rs 26.33 crore. PBIDT rose 5.85% to Rs 377.68 crore. Provision for interest rose 620.55% to Rs 5.26 crore.
PBDT rose 4.59% to Rs 372.42 crore. Provision for depreciation rose 21.55% to Rs 41.29 crore.
Profit before tax grew 2.80% to Rs 331....
Pleaselogin & subscribe to view the full report.
More Reports
|
|